San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Hims & Hers Health and Novo Nordisk announced a partnership a few months ago, and it has already come to an end. Novo Nordisk ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

Dudum, Hims & Hers chief executive, said on social media site X that the telehealth provider would still provide a variety of treatments including Wegovy.

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Hims & Hers began selling compounded semaglutide (Wegovy) in May 2024, which has helped fuel the company's success over the past year.